Halozyme Therapeutics (HALO) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. QCOM
6. EXPE
7. FSLY
8. CPAY
9. FICO
10. PAYC

Go back to Halozyme Therapeutics (HALO) Tops Q2 EPS by 1c

Halozyme Reports Second Quarter 2017 Results

August 8, 2017 4:05 PM EDT

SAN DIEGO, Aug. 8, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the second quarter ended June 30.

"A clear highlight of the second quarter was approval of Genentech's RITUXAN HYCELATM in the U.S., and the resulting strong interest from new potential partners who seek to coformulate with our ENHANZE® technology," said Dr. Helen Torley, president and chief executive officer. "We have strong momentum in the ENHANZE® business with continued growth in royalties and... More